Press & News

The next generation biopharmaceuticals

Press releases

2018-05-11

Affibody Presents at Bio€quity Europe

Solna, Sweden, May 11, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that it is presenting the company at Bio€quity Europe, an investor and partnering event.[read more]

Older press releases

2018-05-09

Kallelse till årsstämma

Aktieägarna i Affibody Medical AB (publ) kallas härmed till årsstämma onsdagen den 13 juni 2018 klockan 13.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.[read more]

2018-03-21

Affibody Announces First Psoriasis Patients Dosed in a Phase II Clinical Trial of ABY-035

Solna, Sweden, March 21, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced dosing of the first patients in a Phase II proof-of-concept study of ABY-035 in patients with moderate-to-severe...[read more]

2018-03-13

Affibody Announces First Dosing in a Phase I Trial of ABY-039 for Autoimmune Diseases

Solna, Sweden, March 13, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced first dosing in a Phase I proof-of-principle study of ABY-039, a potential best-in-class therapy for the treatment...[read more]

Affibodys latest Press releases

2018-09-24

New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment

Solna, Sweden, September 24, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report Q2 (August 23, 2018)

Investor information